University of Texas's MD Anderson Cancer: Combination Immunotherapy Improves Survival for Patients With Asymptomatic Melanoma Brain Metastases
November 11, 2021
November 11, 2021
HOUSTON, Texas, Nov. 11 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Nov. 10, 2021:
* * *
Long-term follow-up of Phase II study shows 71.9% overall survival
* * *
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with melanoma that has spread to the brain, according to Phase II study results published to . . .
* * *
Long-term follow-up of Phase II study shows 71.9% overall survival
* * *
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with melanoma that has spread to the brain, according to Phase II study results published to . . .